作者
Matthew J Gorman, Nita Patel, Mimi Guebre-Xabier, Alex L Zhu, Caroline Atyeo, Krista M Pullen, Carolin Loos, Yenny Goez-Gazi, Ricardo Carrion, Jing-Hui Tian, Dansu Yuan, Kathryn A Bowman, Bin Zhou, Sonia Maciejewski, Marisa E McGrath, James Logue, Matthew B Frieman, David Montefiori, Colin Mann, Sharon Schendel, Fatima Amanat, Florian Krammer, Erica Ollmann Saphire, Douglas A Lauffenburger, Ann M Greene, Alyse D Portnoff, Michael J Massare, Larry Ellingsworth, Gregory Glenn, Gale Smith, Galit Alter
发表日期
2021/9/21
期刊
Cell Reports Medicine
卷号
2
期号
9
出版商
Elsevier
简介
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 …
学术搜索中的文章
MJ Gorman, N Patel, M Guebre-Xabier, AL Zhu… - Cell Reports Medicine, 2021